134 related articles for article (PubMed ID: 23199820)
21. A comparison of radiographic and clinical outcomes of anterior lumbar interbody fusion performed with either a cellular bone allograft containing multipotent adult progenitor cells or recombinant human bone morphogenetic protein-2.
Lee DD; Kim JY
J Orthop Surg Res; 2017 Aug; 12(1):126. PubMed ID: 28841904
[TBL] [Abstract][Full Text] [Related]
22. RE: complications attributable to the use of rhBMP-2 inside the femoral ring allograft during anterior lumbar interbody fusion.
Smoljanovic T; Pecina M
Spine J; 2008; 8(2):413-4; author reply 414. PubMed ID: 18178134
[No Abstract] [Full Text] [Related]
23. RhBMP-2-induced radiculitis in patients undergoing transforaminal lumbar interbody fusion: relationship to dose.
Villavicencio AT; Burneikiene S
Spine J; 2016 Oct; 16(10):1208-1213. PubMed ID: 27343729
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness and safety of recombinant human bone morphogenetic protein-2 versus local bone graft in primary lumbar interbody fusions.
Adams CL; Ogden K; Robertson IK; Broadhurst S; Edis D
Spine (Phila Pa 1976); 2014 Jan; 39(2):164-71. PubMed ID: 24153173
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis.
Fu R; Selph S; McDonagh M; Peterson K; Tiwari A; Chou R; Helfand M
Ann Intern Med; 2013 Jun; 158(12):890-902. PubMed ID: 23778906
[TBL] [Abstract][Full Text] [Related]
26. Science please.
Zdeblick TA
Spine J; 2011 Jul; 11(7):686; author reply 687-90. PubMed ID: 21767996
[No Abstract] [Full Text] [Related]
27. Vertebral body osteolysis after minimal-access transforaminal interbody fusion.
Lehman RA
Spine J; 2011 Jun; 11(6):581-2. PubMed ID: 21729806
[No Abstract] [Full Text] [Related]
28. Does recombinant human bone morphogenetic protein-2 use in adult spinal deformity increase complications and are complications associated with location of rhBMP-2 use? A prospective, multicenter study of 279 consecutive patients.
Bess S; Line BG; Lafage V; Schwab F; Shaffrey CI; Hart RA; Boachie-Adjei O; Akbarnia BA; Ames CP; Burton DC; Deverin V; Fu KM; Gupta M; Hostin R; Kebaish K; Klineberg E; Mundis G; O'Brien M; Shelokov A; Smith JS;
Spine (Phila Pa 1976); 2014 Feb; 39(3):233-42. PubMed ID: 24477081
[TBL] [Abstract][Full Text] [Related]
29. Bone Morphogenetic Proteins in Spinal Surgery: What Is the Fusion Rate and Do They Cause Cancer?
Malham GM; Giles GG; Milne RL; Blecher CM; Brazenor GA
Spine (Phila Pa 1976); 2015 Nov; 40(22):1737-42. PubMed ID: 26730525
[TBL] [Abstract][Full Text] [Related]
30. Pseudo-Pedicle Heterotopic Ossification From Use of Recombinant Human Bone Morphogenetic Protein 2 (rhBMP-2) in Transforaminal Lumbar Interbody Fusion Cages.
Rosen CD; Kiester PD; Lee TQ
Am J Orthop (Belle Mead NJ); 2018 Jan; 47(1):. PubMed ID: 29447305
[TBL] [Abstract][Full Text] [Related]
31. Neuroforaminal chondrocyte metaplasia and clustering associated with recombinant bone morphogenetic protein-2 usage in transforaminal lumbar interbody fusion.
Christensen TJ; Annis P; Hohl JB; Patel AA
Spine J; 2014 Jun; 14(6):e23-8. PubMed ID: 24291359
[TBL] [Abstract][Full Text] [Related]
32. Yet another reason for improving approval and surveillance processes for health technologies.
Kovacs FM; Olabe J; Urrútia G; Zamora J; Bagó J; Alvarez-Galovich L; Abraira V;
Spine J; 2011 Aug; 11(8):800-1; author reply 801. PubMed ID: 21778121
[No Abstract] [Full Text] [Related]
33. Retrograde ejaculation after anterior interbody lumbar fusion.
Tiusanen H; Seitsalo S; Osterman K; Soini J
Eur Spine J; 1995; 4(6):339-42. PubMed ID: 8983652
[TBL] [Abstract][Full Text] [Related]
34. Symptomatic heterotopic bone formation after rhBMP-2 utilization in lateral lumbar interbody fusion.
Aichmair A; Girardi FP; Hughes AP; Sama AA; Lebl DR; Cammisa FP
Spine J; 2013 Oct; 13(10):1411-2. PubMed ID: 24139750
[No Abstract] [Full Text] [Related]
35. A biologic without guidelines: the YODA project and the future of bone morphogenetic protein-2 research.
Carragee EJ; Baker RM; Benzel EC; Bigos SJ; Cheng I; Corbin TP; Deyo RA; Hurwitz EL; Jarvik JG; Kang JD; Lurie JD; Mroz TE; Oner FC; Peul WC; Rainville J; Ratliff JK; Rihn JA; Rothman DJ; Schoene ML; Spengler DM; Weiner BK
Spine J; 2012 Oct; 12(10):877-80. PubMed ID: 23199819
[No Abstract] [Full Text] [Related]
36. Bone morphogenetic protein use in spine surgery in the United States: how have we responded to the warnings?
Guzman JZ; Merrill RK; Kim JS; Overley SC; Dowdell JE; Somani S; Hecht AC; Cho SK; Qureshi SA
Spine J; 2017 Sep; 17(9):1247-1254. PubMed ID: 28456674
[TBL] [Abstract][Full Text] [Related]
37. Promoting fusion in minimally invasive lumbar interbody stabilization with low-dose bone morphogenic protein-2--but what is the cost?
Mannion RJ; Nowitzke AM; Wood MJ
Spine J; 2011 Jun; 11(6):527-33. PubMed ID: 20739225
[TBL] [Abstract][Full Text] [Related]
38. Acknowledging the elephant in the room: conflict of interest in industry-sponsored clinical research.
Hart RA
Spine J; 2011 Aug; 11(8):703-4. PubMed ID: 21925414
[No Abstract] [Full Text] [Related]
39. Complications of anterior cervical discectomy and fusion using recombinant human bone morphogenetic protein-2.
Vaidya R; Carp J; Sethi A; Bartol S; Craig J; Les CM
Eur Spine J; 2007 Aug; 16(8):1257-65. PubMed ID: 17387522
[TBL] [Abstract][Full Text] [Related]
40. Cyst-Like Osteolytic Formations in Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2) Augmented Sheep Spinal Fusion.
Pan HC; Lee S; Ting K; Shen J; Wang C; Nguyen A; Berthiaume EA; Zara JN; Turner AS; Seim HB; Kwak JH; Zhang X; Soo C
Am J Pathol; 2017 Jul; 187(7):1485-1495. PubMed ID: 28502475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
